Dare Bioscience Inc (DARE)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2024 | 12-2023 | 12-2022 | 12-2021 | 12-2020 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -4,054 | -30,161 | -30,948 | -38,696 | -27,401 |
| Depreciation Amortization | 42 | 38 | 24 | 26 | 43 |
| Accounts payable and accrued liabilities | -1,930 | 1,358 | -75 | 1,082 | -62 |
| Other Working Capital | 5,814 | -10,427 | 10,700 | 8,728 | 1,543 |
| Other Operating Activity | 5,522 | 336 | 2,211 | 96 | 642 |
| Operating Cash Flow | $5,394 | $-38,857 | $-18,088 | $-28,764 | $-25,235 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | -573 | -629 | -63 | -15 | -18 |
| Investing Cash Flow | $-573 | $-629 | $-63 | $-15 | $-18 |
| Cash Flows From Financing Activities | |||||
| Debt Issued | 562 | 601 | N/A | N/A | 367 |
| Debt Repayment | -581 | -334 | N/A | N/A | N/A |
| Common Stock Issued | 454 | 15,370 | 1,343 | 75,847 | 24,763 |
| Financing Cash Flow | $434 | $15,637 | $1,343 | $75,847 | $25,131 |
| Exchange Rate Effect | -68 | -10 | -196 | -64 | 11 |
| Beginning Cash Position | 10,811 | 34,670 | 51,674 | 4,670 | 4,780 |
| End Cash Position | 15,998 | 10,811 | 34,670 | 51,674 | 4,670 |
| Net Cash Flow | $5,187 | $-23,859 | $-17,005 | $47,005 | $-111 |
| Free Cash Flow | |||||
| Operating Cash Flow | 5,394 | -38,857 | -18,088 | -28,764 | -25,235 |
| Capital Expenditure | -573 | -629 | -63 | -15 | -18 |
| Free Cash Flow | 4,821 | -39,486 | -18,152 | -28,779 | -25,253 |